Skip to main
  1. Stocks
  2. Alnylam Pharmaceuticals
  3. Forecast
ALNY

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals (ALNY) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 46%
Buy 25%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Alnylam Pharmaceuticals is viewed positively because its commercial TTR franchise is still expanding rapidly, with Q3 net product revenue of $1.3B, Amvuttra revenue of $1.13B, and strong US demand growth that leaves substantial untreated patient runway in TTR-CM. Its outlook is further supported by a deep pipeline, led by nucresiran’s differentiated Q6M dosing and stronger knockdown, plus advancing programs in neuroscience and bleeding disorders that could add meaningful long-term growth. Even with 340B and other reimbursement uncertainties, the company ended Q3 with $3.6B in cash and appears positioned to convert clinical execution into durable margin expansion and franchise durability.

Bears say

Alnylam Pharmaceuticals is facing a weaker fundamental setup as management sees no acceleration in 4Q demand, with FY TTR revenue tracking toward the low end of the $4.2B-$4.4B range and Q3 Amvuttra revenue of $1.13B only masking slowing US growth. New UnitedHealthcare Medicare Advantage restrictions starting October 1 and potential 340B reform create payer and reimbursement uncertainty, while gross margin already fell to 72% from 75% in Q2 due to a higher Amvuttra royalty burden. The firm has also reduced FY27 Amvuttra sales estimates by ~12% and peak sales to $8B from ~$10B, leaving limited visibility into sustainable growth despite the broader RNAi pipeline.

Alnylam Pharmaceuticals (ALNY) has been analyzed by 24 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 25% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alnylam Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Alnylam Pharmaceuticals (ALNY) Analyst Forecast & Price Prediction

Get the latest Alnylam Pharmaceuticals (ALNY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Alnylam Pharmaceuticals (ALNY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alnylam Pharmaceuticals (ALNY) Forecast

Analysts have given Alnylam Pharmaceuticals (ALNY) a Buy based on their latest research and market trends.

According to 24 analysts, Alnylam Pharmaceuticals (ALNY) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $307.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $307.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alnylam Pharmaceuticals (ALNY)


Alnylam Pharmaceuticals (ALNY) Analyst Forecast & Price Prediction

Get the latest Alnylam Pharmaceuticals (ALNY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Alnylam Pharmaceuticals (ALNY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ALNY stock data and trends